Clinical trial · Interventional
Fish Oil Versus Statins Versus Placebos in Reducing Atrial Fibrillation in Patients Undergoing Thoracic Surgery for Lung Cancer
A Double Blinded, Randomized Study Comparing the Effectiveness of Fish Oil Supplements, Oral Statins, and Placebo in Reducing the Incidence of Atrial Fibrillation Following a Lung Resection in Patients With Lung Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Terminated due to low accrual.
Summary
Brief summary (as posted)
The goal of this clinical research study is to learn if Lipitor (atorvastatin) or fish oil supplements can help to control side effects of the heart that are commonly seen after lung surgery (such as irregular heartbeat). Researchers also want to learn if one of these drugs is more effective than the other at controlling side effects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Cancers | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Atorvastatin | Drug | — | UNRESOLVED |
| Fish Oil Supplement | Dietary Supplement | — | UNRESOLVED |
| Placebo | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Atorvastatin
- description
- 1 Atorvastatin capsule daily plus 3 Placebo capsules twice a day orally, 5 days pre-surgery.
- interventionNames
- Drug: Atorvastatin
- Other: Placebo
- type
- EXPERIMENTAL
- label
- Fish Oil Supplement
- description
- 3 Fish Oil capsules twice a day plus 1 Placebo capsule daily orally 5 days pre-surgery.
- interventionNames
- Dietary Supplement: Fish Oil Supplement
- Other: Placebo
- type
- PLACEBO_COMPARATOR
- label
- Placebo
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Patients need to be in a normal sinus rhythm preoperatively. 2. Participants undergoing planned lobectomy and 60 years of age or older or participants undergoing planned pneumonectomy and 18 years of age or older. 3. Planned procedure is 5 days after the start of taking study drugs. 4. Signed written informed consent 5. Women of childbearing potential must have a negative pregnancy test (A woman of childbearing potential is a women who has not been naturally postmenopausal for at least 12 consecutive months or who has not undergone previous surgical sterilization) 6. Adequate liver function evidenced by; aspartate aminotransferase (AST or SGOT) \</= 2.5 \* Upper Limits of Normal (ULN), and alanine aminotransferase (ALT or SGPT) \</= 2.5 \* ULN Exclusion Criteria: 1. Any history of supraventricular arrhythmia for which the patient is taking medications. 2. Current use of antiarrhythmic medications other than beta-receptor antagonists, calcium-channel antagonists, or digitalis. 3. Use of any supplemental n-3 fatty acids during the previous three months. 4. Use of any statin therapy during the previous three months. 5. Patients known to have a history of recent drug or alcohol abuse. 6. Known allergy to seafood 7. Current use of Gemfibrozil and Fenofibrate.
References
Publications (0)
Data not yet available